DALLAS, March 13, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Hidradenitis Suppurativa - Pipeline Review, H1 2015" therapeutic market research report provides an overview of the Hidradenitis Suppurativa's therapeutic pipeline.
The report Hidradenitis Suppurativa - Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Hidradenitis Suppurativa. Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. This condition is a chronic disabling disorder that relentlessly progresses, frequently causing keloids, contractures, and immobility. See the image below. This condition is slightly more common in women and African-Americans. Tight fitting clothing and shaving the areas are to be strictly avoided. Dirt does not cause hidradenitis. Hidradenitis is more common in people who have had acne. It may be an unusual type of adult acne.
This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hidradenitis Suppurativa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies discussed in this report include:
- AbbVie Inc.
- Delenex Therapeutics AG
- Johnson & Johnson
Drugs profile discussed in this report include: adalimumab, adalimumab biosimilar, DLX-105, DLX-2751, ustekinumab.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310174 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases cover by this report include: Oct 13, 2014: AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress; Sep 11, 2014: AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease; Sep 11, 2014: Delenex Announces New Clinical Data; Oct 03, 2013: AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA in Patients with Hidradenitis Suppurativa; Mar 15, 2012: Abbott Announces Patient Enrollment In Two Phase III Studies Of HUMIRA For Moderate To Severe Hidradenitis Suppurativa.
Scope of this report includes: a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Hidradenitis Suppurativa and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; review of the Hidradenitis Suppurativa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Hidradenitis Suppurativa pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products.
Explore more reports of Dermatology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics .
Related reports on Dermatology therapeutics:
Hyper Pigmentation - Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Hyper Pigmentation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include Kasiak Research Pvt. Ltd., MediQuest Therapeutics, Inc., RXi Pharmaceuticals Corporation. Complete report available at http://www.rnrmarketresearch.com/hyper-pigmentation-pipeline-review-h1-2015-market-report.html .
Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer). Companies discussed in this report include Adocia, CardioVascular BioTherapeutics, Inc., CoDa Therapeutics, Inc., CytoTools AG, FirstString Research, Inc., Intralytix, Inc., MacroCure Ltd., Pergamum AB, RegeneRx Biopharmaceuticals, Inc., Smith & Nephew Plc, Stratatech Corporation.
Drugs profiles discussed in this report includes Cathelicidin, Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers, CL-05, CODA-001, CureXcell, CVBT-141B, Granexin, HP-802247, LL-37, Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases, RGN-137, WPP-201. Complete report available at http://www.rnrmarketresearch.com/venous-leg-ulcers-crural-ulcer-pipeline-review-h1-2015-market-report.html .
Chronic Plaque Psoriasis - Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. Companies discussed in this report include AbGenomics International, Inc., Actelion Ltd, Almirall, S.A., ApoPharma Inc., Biotest AG, Boehringer Ingelheim GmbH, Can-Fite BioPharma Ltd., Coherus BioSciences, Inc., Covagen AG, Eli Lilly and Company, GlaxoSmithKline plc, Mitsubishi Tanabe Pharma Corporation, Novartis AG, OPKO Health, Inc., Pfizer Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Takeda Pharmaceutical Company Limited, UCB S.A., XenoPort, Inc. Complete report available at http://www.rnrmarketresearch.com/chronic-plaque-psoriasis-pipeline-review-h1-2015-market-report.html .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect with Us:
G+ / Google Plus: https://plus.google.com/u/0/104156468549256253075/
RSS / Feeds: http://www.rnrmarketresearch.com/feed
SOURCE RnR Market Research